Cong Ye

Cong Ye

Auto-generated profile, based on publicly available information

Cong Ye

Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
DDDonye Dominguez
Donye Dominguez
CYCong Ye
Cong Ye
ZGZhe Geng
Zhe Geng
SCSiqi Chen
Siqi Chen
JFJie Fan
Jie Fan
BZBin Zhang
Bin Zhang
The role of IL-33, particularly in tumor growth and tumor immunity, remains ill-defined. We show that exogenous IL-33 can induce robust antitumor effect through a CD8+ T cell–dependent mechanism. Systemic administration of rIL-33 alone was sufficient to inhibit growth of established tumors in transplant and de novo melanoma tumorigenesis models. Notably, in addition to a direct action on CD8+ T cell expansion and IFN-γ production, rIL-33 therapy activated myeloid dendritic cells (mDCs) in tumor-bearing mice, restored antitumor T cell activity, and increased Ag cross-presentation within the tumor microenvironment. Furthermore, combination therapy consisting of rIL-33 and agonistic anti-CD40 Abs demonstrated synergistic antitumor activity. Specifically, MyD88, an essential component of the IL-33 signaling pathway, was required for the IL-33–mediated increase in mDC number and upregulation in expression of costimulatory molecules. Importantly, we identified that the IL-33 receptor ST2, MyD88, and STAT1 cooperate to induce costimulatory molecule expression on mDCs in response to rIL-33. Thus, our study revealed a novel IL-33–ST2–MyD88–STAT1 axis that restores mDC activation and maturation in established cancer and, thereby, the magnitude of antitumor immune responses, suggesting a potential use of rIL-33 as a new immunotherapy option to treat established cancer.

15 January 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CYCong Ye
Cong Ye
ZGZhe Geng
Zhe Geng
DDDonye Dominguez
Donye Dominguez
SCSiqi Chen
Siqi Chen
JFJie Fan
Jie Fan
BZBin Zhang
Bin Zhang
α-Difluoromethylornithine (DFMO) is currently used in chemopreventive regimens primarily for its conventional direct anticarcinogenesic activity. However, little is known about the effect of ornithine decarboxylase (ODC) inhibition by DFMO on antitumor immune responses. We showed in this study that pharmacologic blockade of ODC by DFMO inhibited tumor growth in intact immunocompetent mice, but abrogated in the immunodeficient Rag1−/− mice, suggesting that antitumor effect of DFMO is dependent on the induction of adaptive antitumor T cell immune responses. Depletion of CD8+ T cells impeded the tumor-inhibiting advantage of DFMO. Moreover, DFMO treatment enhanced antitumor CD8+ T cell infiltration and IFN-γ production and augmented the efficacy of adoptive T cell therapy. Importantly, DFMO impaired Gr1+CD11b+ myeloid-derived suppressor cells (MDSCs) suppressive activity through at least two mechanisms, including reducing arginase expression and activity and inhibiting the CD39/CD73-mediated pathway. MDSCs were one primary cellular target of DFMO as indicated by both adoptive transfer and MDSC-depletion analyses. Our findings establish a new role of ODC inhibition by DFMO as a viable and effective immunological adjunct in effective cancer treatment, thereby adding to the growing list of chemoimmunotherapeutic applications of these agents.

1 April 2020 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
JTJungen Tang
Jungen Tang
SCShaozhe Cai
Shaozhe Cai
CYCong Ye
Cong Ye
LDLingli Dong
Lingli Dong
ImmunoglobulinG4-related disease (IgG4-RD) is a recently recognized disease and, as such, there is a pressing need to identify biomarkers for diagnosis, monitoring disease activity, and predicting prognosis and response to therapy. Here, we review the recent development and identification of biomarkers for IgG4-RD. Through extensive literature review and analysis, we updated the biomarkers for IgG4-RD and further put forward our own viewpoints. In addition to traditional biomarkers, such as serum IgG4 concentration and typical histological characteristics, several novel indicators, including IgG2, serum soluble IL-2 receptor (sIL2R), and cc-chemokine ligand 18 (CCL18), indicate inflammation and fibrosis and can be used to accurately diagnose and predict treatment response. Studies to identify target autoantigens in IgG4-RD have shed light on the unmet need for biomarkers that can identify this disorder. Additionally, both serological and histopathologic immune cells involved in antigen-induced responses, innate immune cells (macrophages, mast cells, and the I-IFN/ IL-33 pathway), as well as subsequent acquired immune cells (T and B cell subsets), may also serve as new biomarkers for IgG4-RD. Since IgG4-RD often clinically manifests with multiple organs involvement, non-invasive PET-CT can improve diagnosis and antidiastole levels. These novel biomarkers provide information to help diagnose IgG4-RD, monitor disease activity, as well as predict prognosis and response to therapy.

19 January 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SCShaozhe Cai
Shaozhe Cai
ZHZiwei Hu
Ziwei Hu
YCYu Chen
Yu Chen
YCYuxue Chen
Yuxue Chen
BMBingxia Ming
Bingxia Ming
LDLingli Dong
Lingli Dong

1 January 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
BMBingxia Ming
Bingxia Ming
TWTong Wu
Tong Wu
SCShaozhe Cai
Shaozhe Cai
PHPeng Hu
Peng Hu
JTJungen Tang
Jungen Tang
LDLingli Dong
Lingli Dong
Objective . The aim of this study was to characterize the subsets of circulating CD56 + NK cells in pSS patients and their potential value in the diagnosis and/or prediction of prognosis in patients with pSS. Methods . We included 52 pSS patients fulfilling the 2002 AECG criteria or 2012 ACR criteria and 20 age‐ and gender‐matched healthy volunteers. The frequency and absolute number of NK cells and CD56 NK cell subsets in peripheral blood samples were detected by flow cytometry. Other laboratory parameters such as the IgG level and complement protein levels were extracted from the clinical system. Results . Both the frequency and the absolute number of peripheral blood NK cells were reduced in pSS patients compared to healthy controls. The proportion of CD56 bright NK cell subset was increased, and the proportion of CD56 dim NK cell subset was decreased among NK cells, resulting in the ratio of CD56 bright NK to CD56 dim NK which was significantly elevated in pSS patients. ROC analysis indicated that the AUC of CD56 bright NK/CD56 dim NK ratio was 0.838, and the best diagnostic cut‐off point was 0.0487 for pSS patients. Furthermore, this CD56 bright NK/CD56 dim NK ratio was positively correlated with the IgG level and negatively correlated with the complement protein C3 and C4 levels. More importantly, the CD56 bright /CD56 dim NK ratio was either slightly increased or not changed in other autoimmune diseases such as SLE and IgG4‐related disease. Conclusion . Our findings suggest that the ratio of blood CD56 bright NK to CD56 dim NK might have a diagnostic value relatively specific for pSS.

24 July 2019 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SCShaozhe Cai
Shaozhe Cai
BMBingxia Ming
Bingxia Ming
CYCong Ye
Cong Ye
SLSheng-Yan Lin
Sheng-Yan Lin
PHPeng Hu
Peng Hu
LDLingli Dong
Lingli Dong
Rheumatoid arthritis (RA) and osteoarthritis (OA) are common rheumatic disorders that primarily involve joints. The inflammation of the synovium can be observed in both of the two diseases. Synovial fibroblasts (SFs) play an important role in the inflammatory process of the synovium. The functional states of synovial fibroblasts are heterogeneous, and the detailed transition process of their functional states is still unclear. By using transcriptomic data of SFs at a single-cell level, we found a similar transition process for SFs in RA and OA. We also identified the potential regulatory effects of the WNT signaling pathway, the TGF-βsignaling pathway, the FcεRI signaling pathway, and the ERBB signaling pathway on modifying the SFs’ functional state. These findings indicate potentially overlapped pathogenic mechanisms in these two diseases, which may help uncover new therapeutic targets to ameliorate disease progression.